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A recent multi-country study on hormonal contraceptives (HC) and HIV acquisition and transmission among African HIV-
serodiscordant couples reported a statistically significant doubling of risk for HIV acquisition among women as well as
transmission from women to men for injectable contraceptives. Together with a prior cohort study on African women seeking
health services, these data are the strongest yet to appear on the HC-HIV risk. This paper will briefly review the Heﬀron
study strengths and relevant biological and epidemiologic evidence; address the futility of further trials; and propose instead
an alternative framework for next steps. The weight of the evidence calls for a discontinuation of progestin-dominant methods.
We propose here five types of productive activities: (1) scaling injectable hormones down and out of the contraceptive mix; (2)
strengthening and introducing public health strategies with proven potential to reduce HIV spread; (3) providing maximal choice
to reduce unplanned pregnancy, starting with quality sexuality education through to safe abortion access; (4) expanding provider
training, end-user counseling and access to male and female barriers, with a special renewed focus on female condom; (5) initiating
a serious research agenda to determine anti-STI/HIV potential of the contraceptive cervical cap. Trusting women tomake informed
choices is critical to achieve real progress in dual protection.
1. Introduction
The recent Heﬀron et al. [1] multi-country study on
hormonal contraceptives (HC) and HIV acquisition and
transmission among African HIV-serodiscordant couples
reported a statistically significant doubling of risk for HIV
acquisition among women as well as transmission from
women to men for injectable contraceptives. A more modest
eﬀect in the same direction was was also reported for com-
bination oral contraceptives (COCs), although not attaining
statistical significance. This study, together with Morrison et
al.’s analyses [2, 3] on a cohort of African women seeking
health services, represents the strongest data yet to appear on
the association. It is unlikely that other study designs, includ-
ing a randomized controlled trial (RCT), could provide
stronger evidence for causal inference. Therefore goes our
argument: these studies provide the weight of the evidence
and the best we can get for the next decade.
Of course, one study, however good, cannot make for
certainty. But by now there have been over 50 published
papers and several comprehensive reviews, emphasizing
the diﬀerent study populations and analytic strategies and
designs, all mainly emanating from high prevalence sites.
Overall, the results for DMPA have shown at least a modest
risk for HIV, not necessarily statistically significant depend-
ing mainly on sample size. Studies not indicating risk often
have serious methodologic shortcomings, such as infrequent
timing of exposure and outcome ascertainment [4], poor
statistical power [5], or aberrant comparison groups [6].
However, Morrison et al., the author of the editorial
accompanying the Lancet issue that published Heﬀron et
al., and who has published other major works in this field,
particularly emphasized the additional risks among young
women. A recent study from South Africa demonstrated
a raised risk of DMPA that only marginally failed to
reach statistical significance and suggested that NET-EN,
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the alternative injectable contraceptive used especially by
young women in South Africa, might also be a risk factor
though of lesser magnitude [7]; a second South African
study also found a significant association of DMPA with
chlamydia infection [8]. Neither the recent CROI nor
microbicide meetings, in which these relationships were
intensively discussed, showed any data to challenge seriously
the relationships outlined here. The immunosuppressive
eﬀects of DMPA may bring other health risks that are
particularly pronounced among young women. For example,
recent data have indicated a doubling of risk for breast cancer
in women aged 20–44 years associated with recent or longer
term (>1 yr) use of this method [9].
This article will cover four issues: first, review the
strengths of the Heﬀron study; second, reexamine and
update biological and epidemiologic evidence to support
the HC-HIV association; third, address the likely futility
of further trials on this association; and finally propose an
alternative framework for next steps.
2. Epidemiological Strengths of Heffron
Heﬀron et al. addressed a large and vulnerable high-
risk population. The study followed close to 4000 HIV-
serodiscordant couples across seven African countries for
which HSV-2 infection status was known for each partner.
Importantly, timing of the acquired HIV infections was
tightly linked to the exposure period, a problem in numerous
prior studies. The analysis excluded infections among men
from an outside partner, via genetic testing of the HIV-
1 virus, thus assuring the firmest possible control over
HIV exposure source. Contraceptive exposure information
was updated quarterly; self-report was validated and study
sites often were the providers of the contraceptive methods
(personal communication, Helen Rees). Finally, participant
retention was high (over 90% at 12 months; over 84% at
24 months), minimizing threat of selective loss-to-follow-
up. These four study aspects lent great strength of inference
to the observed association. Study aspects leading to weaker
causal inference included self-report as the source of infor-
mation on condom use and sexual frequency. Nevertheless,
superior methods for collecting or validating information
on these exposures in such a study setting are not possible.
The sexual behavior variables were controlled in numerous
analytical approaches. Adjustment in Heﬀron strengthened
the observed eﬀect estimate and narrowed the confidence
intervals. In Heﬀron, as in the Morrison analyses preceding,
multiple statistical approaches undertaken to control eﬀects
of these confounders, moving from less rigorous to more
rigorous approaches, did not undermine the observed eﬀect
and, as also in Morrison et al., demonstrated a strengthening
of the eﬀect estimate. Heﬀron and coauthors recently pre-
sented sensitivity analyses [10] demonstrating a persistence
of the eﬀect on HIV risk found in their original analysis.
Of note, when restricting the analysis to consistent DMPA-
users only (i.e. excluding South African women who also
use Net-En), the risk (hazard ratio) climbed substantially,
to 3.39 (CI 1.38–11.22). Also of interest, and found in
other data sets, COCs, containing a lower dose of progestin,
showed weaker eﬀects on HIV risk (see also biology, below).
Alternate explanations for this result, that entirely exclude an
actual biological eﬀect, are diﬃcult to formulate.
Finally, that Heﬀron et al. represented a secondary
analysis has been repeatedly emphasized as an important
shortcoming; yet this would not appear to detract signifi-
cantly from epidemiologic inference. Certainly, the number
of hormonal contraceptive users was smaller than in a study
explicitly designed to assess this association, resulting in
relatively wide confidence intervals. Nevertheless, concern
that the Heﬀron analysis, due to its secondary nature,
demonstrated “chance findings” is unwarranted. The like-
lihood that there is no underlying eﬀect of HC on HIV
risk, when posed against the substantial body of biologically
coherent data and epidemiologic evidence in favor of this
association generated over 2 decades [11], is vanishingly
small.
3. Supportive Biological
Evidence and Coherence
There is no dearth of accrued biological evidence supportive
of an increased risk of HIV infection due to endogenous
or synthetic progesterone exposure; indeed, numerous bio-
logical mechanisms might act synergistically. Marx and
colleagues in 1986 in macaques [12] demonstrated increased
dramatic thinning of vaginal lining as well as susceptibility
to SHIV with progestin treatment. Indeed, progesterone
treatment is routinely used in experimental animal protocols
to achieve infection. Eﬀects of progesterone to explain
the observed role in infection of monkeys include vaginal
thinning and loss of keratinization of the epithelial layer,
but remain less clear. In humans, Mauck and colleagues
[13] found only a modest amount of epithelial thinning
in a small series of American women administered DMPA,
inconsistent with the degree of thinning seen in Marx
et al., thereby weakening a biological plausibility argument
through analogy with the monkey data. But recent data
from Vishwanathan and colleagues [14] demonstrate SHIV
infection risk is increased with only a modestly higher level
of progestin, and a small degree of thinning that accompanies
the progesterone-dominant phases of the menstrual cycle of
pigtail macaques. This study has challenged the argument for
vaginal thinning as one mediator of HIV infection.
Other potential mechanisms to explain an increase in
infection risk for women using HC include, on a clinical
level, cervical ectopy (ectopy is typically associated with
immaturity; Morrison et al. [2, 3] found HIV risk with use
of DMPA more marked among young women but a recent
study did not support the association [15]), or mediating
eﬀects of genital tract infection, and related impact and role
of Lactobacillus colonization of the vagina; and on a cellular
level, cervicovaginal inflammation and viral replication [16].
One study of high-risk women demonstrated that HC users
were more likely than non-users to become simultaneously
infected with more than one variant of HIV-1 [17, 18].
Kumwenda and colleagues [19] who measured HIV viral
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load quarterly among women attending general reproductive
health services in Malawi, demonstrated both a strong
association of DMPA with seroconversion, as well as an
interaction of DMPA use with increased viral load around
the time of acute infection. No association of DMPA was
seen for disease progression. The findings accented the
critical nature of the timing of ascertainment of exposure to
detection of any underlying HC-HIV association.
Hel and colleagues [20] have extensively reviewed the
multiple immunoregulatory eﬀects of progesterone. Estro-
gen treatment is noted to protect macaques against infection;
thus providing some biological coherence to the observation
in numerous epidemiologic studies, that COCs are associated
with a lower risk of HIV acquisition in women, as compared
with DMPA, even when controlling for sexual behavior [3,
7, 16, 21]. Progesterone treatment in some studies increases
frequency of Langerhans cells in the vaginal epithelium,
an important target cell in HIV early infection events.
Chandra et al. [22] recently reported significant increases
in vaginal T cells, activation markers, and HIV-1 receptors
among healthy women measured at 12 weeks following
DMPA administration. Estrogen treatment is associated with
a decreased frequency of these cells [20]. Other data converge
to strongly support the contention that physiological changes
in progesterone exposure during the menstrual cycle account
for large diﬀerences in infection risk [23].
4. Is a Randomized Controlled Trial (RCT)
Called for and Feasible?
There have been calls for an RCT to strengthen epidemiologi-
cal inference on HC-HIV risk [24]. It is unlikely that an RCT,
however well-designed, would answer the shortcomings of
the present, large, observational data set. The main gaps
in Heﬀron et al., confirmation of condom use and coital
frequency, are diﬃcult to fill.
First, it is unlikely that any single RCT could replicate
or improve on the population diversity represented in the
observational data. Exposure interactions with variables
such as high-risk sexual behavior, concurrent STI, vaginal
ecology variables, and other covariates, all of which may
be important in the risk equation, could be entirely missed
in the narrow select population of any RCT. Women who
agree to be randomized to a contraceptive method (e.g.,
Depo Provera injection versus IUD)may be diﬀerent in some
important ways among women who would and would not
be recruited, limiting the chances to detect an underlying
association. Clinical inclusion/exclusion criteria will lead
to further homogeneity of the population. Second, it is
unlikely that the study could blind women to their assigned
method, thereby raising the risk of diﬀerential condom
use and other sexual behaviors (e.g., sexual frequency) in
response to the method’s secondary eﬀects or perceived
method attributes or eﬃcacy. This undermines a primary
rationale for trial design. Such behaviors will need to be
captured by self-report, as with observational design; self-
report of behaviors may thereby be diﬀerential by trial arm.
Third, method side eﬀects (such as nausea, breast tenderness,
and intermittent bleeding for DMPA), historically a primary
cause of discontinuation, would not be altered by trial design.
Discontinuation, method switching, and/or poor adherence
would reduce the statistical power of the trial to identify
and quantify risks with HC, and is a serious threat to
trial success. These considerations imply that a trial carries
a substantial likelihood of missing an actual, underlying
diﬀerence in HIV risk with hormonal methods, with the
attendant false reassurance of safety. Adherence has been
a serious challenge in other large trials of FP methods.
Fourth, the assignment of trial arms will certainly be a
conundrum. IUDs may pose their own risks of increased
STI/HIV; concerns regarding PID are still current (see
below). Comparing diﬀerent hormonal products with each
other will require a sample size that may be unattainable
and certainly an outstanding resource commitment. Absence
of a condom arm would hinder inference considerably; if
hormonal and IUD arms are equivalent in HIV risk, what
shall we conclude about the relative risk for women using
condoms? Yet, randomizing women to nonhormonal/non-
IUD contraception reproduces the potential for unequal use
of condoms across arms, as mentioned above. Also, ethical
arguments have been expressed in relation to randomizing
women to a male condom-only condition where partner
cooperation is required and often not realized [25].
In short, a RCTwould be unlikely to yield greater insights
into this issue, but would cost us another better part of a
decade to design, conduct, and analyze, during which time
HIV incidence would continue to climb, and FP program
adaptation would be delayed. The reflexive move toward an
RCTmust be resisted; theoretical gains of randomized design
would not be achieved in practice, as outlined above. The
momentum of the scale-up of DMPA in FP programs over
the past decade must also be considered in the risk equation
and timeline to response—the yearly cost in HIV infections
secondary to use of injectables has not yet reached its apex,
placing an even greater urgency on decisions to change policy
and discontinue use of this contraceptive method. Further,
the data in Heﬀron pointed to a doubling of the risk of HIV
transmission to the male partner with use of DMPA. This is
the first such report and although not confirmed elsewhere,
provides additional arguments for moving this method out
of the contraceptive mix as quickly as possible.
A change in paradigm favoring the scale-up of safer,
health-preserving contraceptives to men and women in low-
resource, high-HIV risk settings brings clear benefits for gen-
erations to come. By contrast the marginal gains to be had in
squandering precious resources on a further trial of DMPA,
even with the highly optimistic and unlikely assumption that
such a trial will be “perfect” and unimpeachable, are small.
The move to safer contraceptives is inevitable, as is the need
to decide policy in a state of scientific uncertainty.
5. Next Steps: Living with Uncertainty,
Acting in Best Interests of Women
Taken together, the biological evidence and epidemiologic
evidence from Heﬀron et al., and Morrison et al. while
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not definitively ending the debate on whether HCs raise
risk of HIV, have nevertheless tipped the scale considerably
in favor of a presumption of risk, especially for progestin-
dominant injectables. It is no longer ethically justifiable to
“stay the course” with current FP programming; the weight
of the evidence supports a move away from promotion of
progestin-dependent methods.
This altered course, then, calls for at least five diﬀerent
types of activities, of which our main focus for this article
shall be on the last two.
Scaling injectable hormones down and out of the con-
traceptive mix and bolstering provider training as well as
counseling activities to support full disclosure policies for users
on risks with these methods. Greatly increased emphasis of
educational approaches, and their evaluation at a range of
sites will be needed. It must be explained to all concerned—
health workers, women at risk, and their partners—that
use of hormonal methods, especially DMPA, likely increases
women’s risk of HIV acquisition. Women cannot be denied
this information and the autonomy to act in their best
interests as they see it. Protecting women “from themselves”
will not advance a women’s health agenda. In our view,
the recent WHO Technical Statement [26] downplays risks
with these products by urging no eﬀective change in policy
while at the same time vigorously promoting use of added
protection against HIV; it is an unclear message that is
hard to decipher for women users. Women should be
dissuaded from initiating use of injectables and informed
about the reasons and concerns; whether in low or high
HIV-prevalence areas, women’s right to the information on
risk and their ability to exercise choice must be paramount.
Counseling should also cite a possible elevated HIV risk
for men though stressing this is unconfirmed and carefully
refocusing responsibility on themale partner to use condoms
for couple protection.
Strengthening and introducing public health strategies
with proven potential to disrupt HIV transmission, including
universal test-and-treat, treatment upon first diagnosis,
circumcision programs, pre- and post-exposure prophylaxis,
whether pills or microbicides, and treatment as prevention
(Truvada). Addressing implementation strategies for combi-
nation prevention is likely to yield large gains in reducing
HIV spread [27]. These will lower community/network
infection prevalence and thus reduce the impact of contra-
ceptive method interactions with HIV exposure.
Providing maximal choice to reduce unplanned pregnancy
to a minimum, from quality sexuality education to diverse
contraceptive methods to emergency contraception and safe
abortion access. Scale-up and promotion of the widest range
of contraceptive methods to address diﬀerent age groups and
diverse partnership contexts should include permanentmethods
(male and female sterilization) lowest dose non-progestogen-
based hormonals, IUDs (with screening and triaging of users),
and male and female condoms—all with careful counseling
regarding risks and benefits and need for consistent use for
coitally dependent methods. Current contraceptive choice in
high-HIV prevalence areas is limited and must now urgently
diversify towards methods that do not increase STI/HIV risk.
Women must be informed that all nonbarrier contraceptives
involve some level of risk (besides contraceptive failure); and
that male and female condoms do not pose these safety risks.
Consistent use is key for coitally-dependent methods and
pills. Women should be full partners in this choice.
IUDs are highly eﬀective and do not involve systemic
exposure to progestogens, with their immunosuppressive
eﬀects [28]. Nevertheless, data remain scarce on possible
eﬀects on risk of HIV acquisition. The evidence on PID risk
is still worrisome for high-STI prevalence areas [29]. Several
authors have oﬀered careful approaches to be used even in
such settings, including, first and foremost, commitment
to quality of care [30], as well as the use of conservative
algorithms to determine candidacy for this method and
presumptive antibiotic treatment for women at highest risk
[30, 31]. Women users should be educated about PID—the
risks and signs and symptoms.
Expand provider training, end-user counseling and access
to male and female barriers—female condoms, diaphragms,
and cervical caps—for sole use, dual use, or multipurpose use,
with renewed focus on hierarchical counseling and use of proven
interventions to ensure optimal uptake. Male condom use is
certainly eﬃcacious, and must continue to be urged; yet,
the enormous obstacles many women face in negotiating
their use with partners remain as valid today as they were
at the start of the HIV epidemic [32]. Though progress
has been made in male condom use rates, a majority
of high-prevalence countries report lack of protection at
last encounter [33]. Indeed, promoting the male condom
now as a satisfactory solution to women’s increased risk
of HIV with injectable hormones only invites a cynical
reception and the planting of the seeds of mistrust in
women due to its seeming head-in-the-sand nature, and
limited usefulness “on the ground”. Cates and Steiner [34],
in an early paper have argued that promoting condoms only
for disease prevention may stigmatize the method. Indeed,
from a woman’s perspective, removing the “contraceptive
justification” for male condom use from the argument
repertoire—for example, where male partners are aware of
hormonal contraceptive use—clearly impacts on likelihood
of partner agreement. Thus, male condoms as the second
(dual) method is likely to appeal only to highly select
population groups such as HIV sero-discordant couples—
those keenly aware of their status and mutually committed
to protection. For others, recourse to female protection
methods is probably still the most promising route. These
arguments together point to the need to expand—in name
and in deed—access to female methods as dual methods.
Proactive promotion of female barriers alongside hormonal
methods must start with specific mention of such methods
in policy or counseling texts. These safe methods could be
promoted both as alternatives to hormonal methods, or to
be used in tandem with them—“oﬀset options”—to mitigate
against risk of infection while bolstering protection against
unplanned pregnancy. Using “hierarchical” strategies [35],
the female condom and male condom should be uniformly
counseled on as equally protective against STI/HIV [36],
with cervical barriers (diaphragms, cervical caps, cups, etc.)
promoted as “next best”; some of these latter should provide
some protection against disease (those infecting the cervix
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mainly or solely) but less than either of the two condoms.
Any serious program of scale-up of female barriers would
also require provider training (across FP-HIV-reproductive
health (RH) facilities) and positive re-orientation of FP
personnel, at all levels, as this has been a serious hindrance
to use historically [37–40]. Recent evidence from a South
African female condom trial quantifies the substantial reduc-
tion in method problems experienced by the user when
adequate user support is provided in the initial adoption
period [41]. There has been a tendency to discount female
barrier methods as impractical and unacceptable though no
wide-scale evidence in developing countries supports this
contention and indeed there is evidence to the contrary [42–
48]. Certainly the existing evidence is wholly insuﬃcient to
glean women’s actual preferences when given real choice, in
an appropriately-designed research study or demonstration
program. Involvement of communities of women users of
contraceptive services, and their partners, will help inform
the most culturally appropriate approaches [40]. Women
have potentially more control over female condom use but
its impact will be realized only with strong promotional
programs and quality counseling including outreach activi-
ties to men wherever possible [49], as well as easy access to
continuing supplies, to ensure adoption and maintenance of
the behavior [36].
Initiation of a serious research agenda to determine
anti-STI/HIV eﬃcacy and eﬀectiveness of an important yet
overlooked contraceptive method: the cervical cap. Covering the
cervix may help reduce HIV risk via: (a) reducing coincidence
of cervical inflammation-HIV contact, (b) blocking sperm-
mediated HIV infection, and (c) among young women (with
immature cervices) for which injectables may carry a very
high increased risk of HIV infection. Advocacy for women-
controlled protection has spawned numerous, exciting direc-
tions aimed at expanding chemical and physical protection
methods for women. Among these, the movement for
multipurpose prevention technologies (MPTs) has as its goal
to develop products with at least two indications (con-
traception, STI prevention, HIV prevention, reproductive
health enhancement) [50]. New cervical barriers under this
rubric include the Silcs diaphragm and tenofovir-releasing
rings [51]. Concurrently with development of new methods,
however, research on conventional, time-tested and approved
female barriers must also proceed with urgency. As one
example, there is a clear need for a RCT to address anti-
HIV eﬃcacy and eﬀectiveness of the cervical cap, and specify
optimal conditions of use as a contraceptive. Although the
contraceptive diaphragm has been the subject of a large-
scale trial for eﬃcacy in HIV/STI prevention [52] (failing to
produce evidence of eﬀectiveness), the cervical cap has so far
been passed over, despite the fact that the device may oﬀer
distinct advantages over other devices now under study and
in development.
5.1. Biological Justification for Cervical Barrier Methods in
Women’s HIV Prevention. HIV infection across the vaginal
wall, as compared to ecto or endocervical transmission—is
thought by many to account for most sexually transmitted
infections in women due to the large diﬀerence in sur-
face area [23]. Nevertheless, considerable questions remain.
In particular, due to the possibility of sperm-mediated
transport of HIV, uterine peristalsis aiding infection of
the upper reproductive tract, and the high prevalence of
cervicitis in the developing world, a clear role for cervical
barriers in reducing risk of HIV infection certainly exists
[53]. Hormonal mediation of HIV receptor cells diﬀers
considerably when comparing upper and lower reproductive
tracts [23, 54]. Protecting the cervix from inflammation
due to infection or trauma, or reduced innate immunity
with exogenous hormonal exposure or menstrual cycle stage
should still be of high interest for reducing risk of HIV.
5.2. Cervical Caps—Eﬃcacy: Mode of Action. Cervical caps
have a distinctly diﬀerent mechanism of protection than
the diaphragm and other “loose” cervical barriers. Like the
contraceptive diaphragm, the cap covers the cervix, but the
shape of the cap is conical, like the cervix, and the device
adheres via gentle suction, rendering the level of protection
to sperm and pathogens theoretically much greater than that
of the diaphragm, because the cap completely surrounds and
encloses the cervix (see Figure 1). The contraceptive eﬃcacy
of cap versus diaphragm, in the two available trials, indicates
a similar level of protection against unplanned pregnancy
[55]; but some of this protection in the case of the diaphragm
is likely owing to simultaneous use of spermicide. Much
remains to be determined regarding actual use-eﬀectiveness
of the cap as a contraceptive or for disease prophylaxis in
populations needing dual protection.
5.3. Cervical Caps—Eﬀectiveness: User Aspects. From the
user’s perspective, there are a great number of advantages to
this particular barrier [56, 57]. It can be used without the
partners’ knowledge, inserted long before sex, and can be
used with the male condom. The cap should be compatible
with all forms of contraception and could be theoretically
quite important in oﬀsetting increased risk of STI/HIV
acquisition with hormonal contraceptives or IUDs if used
concurrently. The cap may be used for multiple acts without
reapplication of spermicide or removal, at a continuous high
level of contraceptive eﬃcacy for at least 48 hours, according
to present FDA labeling; published data indicate longer wear
is possible without safety concerns [58]. Cap devices may
be adapted for microbicide release [59]. These devices are
in general small, simple, and inexpensive to manufacture,
as well as being highly portable, durable, and resistant
to temperature and other environmental conditions. The
Femcap, as the only currently approved and marketed
cervical cap, is made of silicone, thus maximally resistant
with no need for replacement over many years [60, 61]
(Figure 2).
The user advantages above point to potentially large
gains in eﬀectiveness over other cervical barriers when used
as an anti-STI/HIV method. The limited field experience
with the device in developing country populations suggests
acceptability is suﬃciently good for larger trials [62, 63].
Evidence from other hard-to-reach populations such as
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Diaphragm covering
cervix
(a)
Cervical Cap
 covering cervix
(b)
Figure 1: Diaphragm versus cervical cap placement. Courtesy of Rebecca Chalker, The Complete Cervical Cap Guide, copyright 1987.
Figure 2: Femcap (courtesy of Alfred Shihata).
substance-using women suggests the same [64]. An energetic
research agenda could bring large STI/HIV prevention gains
to potentially diverse populations of women in need. Yet
poor global promotion of this device has led to low clinician
familiarity, negative attitudes, and consequent low awareness
and demand among women [60, 65]. The cervical cap needs
an influential champion.
6. Conclusion
There is substantial lack of incentive to altering current FP
policy, due to real concerns about the risks of pregnancy for
women and children, especially in resource-poor countries.
DMPA, as a long-acting, highly promoted, popular contra-
ceptive for women, has a clear public health advantage that
extends beyond reducing unplanned pregnancy rates to the
reduction of maternal mortality and vertical transmission
of HIV infection. Filling the void left by discontinuation
of this method will be neither convenient nor simple.
Nevertheless, we cannot let the diﬃculties be an obstacle
to change. Numerous other contraceptive options exist
and must be deployed with enthusiastic provider support.
The price couples pay for contraception need not be HIV
infection. The recently-confirmed increased HIV risk with
DMPA use has thrown into bold relief our slow progress
at entrusting women with a meaningful range of choices in
contraception that would also protect them from disease.
Increased expectations of women to make up the gap in
new HIV infections acquired due to DMPA, by somehow
suddenly exerting an extraordinary level of control over male
condom use, places the burden squarely on women rather
than health systems to adapt and is not a realistic solution.
Greater emphasis must be given to full frank informational
counseling, and expanded options that women may learn
and practice autonomously to reduce HIV risk concurrently
with practice of contraception. A change in direction could
also promote real bridging and integration across RH,
HIV, and FP “camps”, thus opening up new opportunities
to better serve women and couples in our public health
mission. Finally, the renewed focus on female barrier
methods should prompt an accelerated research agenda and
important step-ups in funding, both for new technologies
we have started to explore, as well as conventional barriers
we have yet to exploit. Culling and generalizing proven,
eﬀective approaches to female condom promotion remains
well within our global capabilities and as yet unrealized. An
additional technology with the potential to reduce sexual
HIV risk, so far neglected, but calling for revival and an
invigorated research campaign, is the cervical cap.
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